Effects of chronic use of phosphodiesterase inhibitors on endothelial markers in type 2 diabetes mellitus: A meta-analysis

European Journal of Endocrinology

Volumn 172, Issue 3, 2015, Pages R103-R114

  Santi, Daniele ^a,b   Giannetta, Elisa ^c   Isidori, Andrea M ^c   Vitale, Cristiana ^d   Aversa, Antonio ^c   Simoni, Manuela ^a,b  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b AUSL Modena   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d San Raffaele University   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; ENDOTHELIN 1; INTERLEUKIN 6; NITRIC OXIDE; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; SILDENAFIL; TADALAFIL; PHOSPHODIESTERASE INHIBITOR;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC DRUG ADMINISTRATION; DIABETIC PATIENT; DRUG EFFECT; DRUG USE; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM; ERECTILE DYSFUNCTION; HEMODYNAMICS; HUMAN; INFLAMMATION; INFORMATION RETRIEVAL; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; VASODILATATION; BLOOD; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; ENDOCRINE SYSTEM DISEASES; FEMALE; MALE; RANDOMIZED CONTROLLED TRIAL (TOPIC); VASCULAR ENDOTHELIUM;

DIABETES MELLITUS, TYPE 2; ENDOCRINE SYSTEM DISEASES; ENDOTHELIUM, VASCULAR; FEMALE; HEMODYNAMICS; HUMANS; INTERLEUKIN-6; MALE; PHOSPHODIESTERASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84923642102     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-14-0700     Document Type: Review

References (64)

1. Moreno G & Mangione CM. Management of cardiovascular disease risk factors in older adults with type 2 diabetes mellitus: 2002-2012 literature review. Journal of the American Geriatrics Society 2013 61 2027-2037. (doi:10.1111/jgs.12513)
2. Wild S, Roglic G, Green A, Sicree R & King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004 27 1047-1053. (doi:10.2337/diacare.27.5.1047)
3. Matthaei S, Stumvoll M, KellererM & Haring HU. Pathophysiology and pharmacological treatment of insulin resistance. Endocrine Reviews 2000 21 585-618.
4. Haffner SM, Lehto S, Ronnemaa T, Pyorala K & Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. New England Journal of Medicine 1998 339 229-234. (doi:10.1056/ NEJM199807233390404)
5. Hellsten Y, Nyberg M, Jensen LG & Mortensen SP. Vasodilator interactions in skeletal muscle blood flow regulation. Journal of Physiology 2012 590 6297-6305. (doi:10.1113/jphysiol.2012.240762)
6. Wen Y, Skidmore JC, Porter-Turner MM, Rea CA, Khokher MA & Singh BM. Relationship of glycation, antioxidant status and oxidative stress to vascular endothelial damage in diabetes. Diabetes, Obesity & Metabolism 2002 4 305-308. (doi:10.1046/j.1463-1326. 2002.00212.x)
7. Hakim LS & Goldstein I. Diabetic sexual dysfunction. Endocrinology and Metabolism Clinics of North America 1996 25 379-400. (doi:10.1016/ S0889-8529(05)70329-7)
8. Taylor AA. Pathophysiology of hypertension and endothelial dysfunction in patients with diabetes mellitus. Endocrinology and Metabolism Clinics of North America 2001 30 983-997. (doi:10.1016/S0889- 8529(05)70223-1)
9. Ahn GJ, Yu JY, Choi SM, Kang KK, Ahn BO, Kwon JW, Kang SK, Lee BC & Hwang WS. Chronic administration of phosphodiesterase 5 inhibitor improves erectile and endothelial function in a rat model of diabetes. International Journal of Andrology 2005 28 260-266. (doi:10.1111/j.1365- 2605.2005.00537.x)
10. Poredos P & Jezovnik MK. Testing endothelial function and its clinical relevance. Journal of Atherosclerosis and Thrombosis 2013 20 1-8. (doi:10.5551/jat.14340)
11. Cho NH, Ahn CW, Park JY, Ahn TY, Lee HW, Park TS, Kim IJ, Pomerantz K, Park C, Kimm KC et al. Prevalence of erectile dysfunction in Korean men with type 2 diabetes mellitus. Diabetic Medicine 2006 23 198-203. (doi:10.1111/j.1464-5491.2005.01789.x)
12. Grover SA, Lowensteyn I, Kaouache M, Marchand S, Coupal L, DeCarolis E, Zoccoli J & Defoy I. The prevalence of erectile dysfunction in the primary care setting: importance of risk factors for diabetes and vascular disease. Archives of Internal Medicine 2006 166 213-219. (doi:10.1001/archinte.166.2.213)
13. Sun P, Cameron A, Seftel A, Shabsigh R, Niederberger C & Guay A. Erectile dysfunction - an observable marker of diabetes mellitus? A large national epidemiological study. Journal of Urology 2006 176 1081-1085 (discussion 1085). (doi:10.1016/j.juro.2006.04.082)
14. De Angelis L, Marfella MA, Siniscalchi M, Marino L, Nappo F, Giugliano F, De Lucia D & Giugliano D. Erectile and endothelial dysfunction in type II diabetes: a possible link. Diabetologia 2001 44 1155-1160. (doi:10.1007/s001250100616)
15. Mazo E, Gamidov S & Iremashvili V. The effect of vardenafil on endothelial function of brachial and cavernous arteries. International Journal of Impotence Research 2006 18 464-469. (doi:10.1038/sj.ijir. 3901454)
16. Carson CC, Burnett AL, Levine LA & Nehra A. The efficacy of sildenafil citrate (Viagra) in clinical populations: an update. Urology 2002 60 12-27. (doi:10.1016/S0090-4295(02)01687-4)
17. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD & Wicker PA. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. New England Journal of Medicine 1998 338 1397-1404. (doi:10.1056/NEJM199805143382001)
18. Schafer A, Fraccarollo D, Pfortsch S, Flierl U, Vogt C, Pfrang J, Kobsar A, Renne T, Eigenthaler M, Ertl G et al. Improvement of vascular function by acute and chronic treatment with the PDE-5 inhibitor sildenafil in experimental diabetes mellitus. British Journal of Pharmacology 2008 153 886-893. (doi:10.1038/sj.bjp.0707459)
19. Milani E, Nikfar S, Khorasani R, Zamani MJ & Abdollahi M. Reduction of diabetes-induced oxidative stress by phosphodiesterase inhibitors in rats. Comparative Biochemistry and Physiology. Toxicology & Pharmacology 2005 140 251-255. (doi:10.1016/j.cca.2005.02.010)
20. Moher D, Altman DG, Liberati A & Tetzlaff J. PRISMA statement. Epidemiology 2011 22 128 (author reply 128). (doi:10.1097/EDE. 0b013e3181fe7825)
21. Moher D, Liberati A, Tetzlaff J & Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. International Journal of Surgery 2010 8 336-341. (doi:10.1016/j.ijsu. 2010.02.007)
22. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ & McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Controlled Clinical Trials 1996 17 1-12. (doi:10.1016/0197-2456(95)00134-4)
23. Sommer F, Klotz T & Engelmann U. Improved spontaneous erectile function in men with mild-to-moderate arteriogenic erectile dysfunction treated with a nightly dose of sildenafil for one year: a randomized trial. Asian Journal of Andrology 2007 9 134-141. (doi:10.1111/j. 1745-7262.2007.00233.x)
24. Attina TM, Malatino LS, Maxwell SR, Padfield PL & Webb DJ. Phosphodiesterase type 5 inhibition reverses impaired forearm exercise-induced vasodilatation in hypertensive patients. Journal of Hypertension 2008 26 501-507. (doi:10.1097/HJH.0b013e3282f382ff)
25. Kaufmann BA, Bernheim AM, Kiencke S, Fischler M, Sklenar J, Mairbaurl H, Maggiorini M & Brunner-La Rocca HP. Evidence supportive of impaired myocardial blood flow reserve at high altitude in subjects developing high-altitude pulmonary edema. American Journal of Physiology. Heart and Circulatory Physiology 2008 294 H1651-H1657. (doi:10.1152/ajpheart.00760.2007)
26. Hirata K, Adji A, Vlachopoulos C & O'Rourke MF. Effect of sildenafil on cardiac performance in patients with heart failure. American Journal of Cardiology 2005 96 1436-1440. (doi:10.1016/j.amjcard.2005.06.091)
27. Oliver JJ, Melville VP & Webb DJ. Effect of regular phosphodiesterase type 5 inhibition in hypertension. Hypertension 2006 48 622-627. (doi:10.1161/01.HYP.0000239816.13007.c9)
28. Vlachopoulos C, Hirata K & O'Rourke MF. Effect of sildenafil on arterial stiffness and wave reflection. Vascular Medicine 2003 8 243-248. (doi:10.1191/1358863x03vm509ra)
29. Desouza C, Parulkar A, Lumpkin D, Akers D & Fonseca VA. Acute and prolonged effects of sildenafil on brachial artery flow-mediated dilatation in type 2 diabetes. Diabetes Care 2002 25 1336-1339. (doi:102337/diacare.25.8.1336)
30. Aversa A, Vitale C, Volterrani M, Fabbri A, Spera G, Fini M & Rosano GM. Chronic administration of Sildenafil improves markers of endothelial function in men with type 2 diabetes. Diabetic Medicine 2008 25 37-44. (doi:10.1111/j.1464-5491.2007.02298.x)
31. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J & Mishra A. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997 49 822-830. (doi:10.1016/S0090-4295(97)00238-0)
32. Yang L, Qian S, Liu L, Pu C, YuanH,Han P & Wei Q. Phosphodiesterase-5 inhibitors could be efficacious in the treatment of erectile dysfunction after radiotherapy for prostate cancer: a systematic review and metaanalysis. Urologia Internationalis 2013 90 339-347. (doi:10.1159/ 000343730)
33. Petrone L, Mannucci E, Corona G, Bartolini M, Forti G, Giommi R & Maggi M. Structured interview on erectile dysfunction (SIEDY): a new, multidimensional instrument for quantification of pathogenetic issues on erectile dysfunction. International Journal of Impotence Research 2003 15 210-220. (doi:10.1038/sj.ijir.3901006)
34. Chandler J, Clarke M & Higgins J. The Cochrane Collaboration. Cochrane Methods. UK: John Wiley & Sons Ltd, 2012.
35. Grover-Paez F, Villegas Rivera G & Guillen Ortiz R. Sildenafil citrate diminishes microalbuminuria and the percentage of A1c in male patients with type 2 diabetes. Diabetes Research and Clinical Practice 2007 78 136-140. (doi:10.1016/j.diabres.2007.02.006)
36. Giannetta E, Isidori AM, Galea N, Carbone I, Mandosi E, Vizza CD, Naro F, Morano S, Fedele F & Lenzi A. Chronic inhibition of cGMP phosphodiesterase 5A improves diabetic cardiomyopathy: a randomized, controlled clinical trial using magnetic resonance imaging with myocardial tagging. Circulation 2012 125 2323-2333. (doi:10.1161/ CIRCULATIONAHA.111.063412)
37. Deyoung L, Chung E, Kovac JR, Romano W & Brock GB. Daily use of sildenafil improves endothelial function in men with type 2 diabetes. Journal of Andrology 2012 33 176-180. (doi:10.2164/jandrol.111.013367)
38. Burnett AL, Strong TD, Trock BJ, Jin L, Bivalacqua TJ & Musicki B. Serum biomarker measurements of endothelial function and oxidative stress after daily dosing of sildenafil in type 2 diabetic men with erectile dysfunction. Journal of Urology 2009 181 245-251. (doi:10.1016/j.juro. 2008.09.005)
39. Goldstein I, Jones LA, Belkoff LH, Karlin GS, Bowden CH, Peterson CA, Trask BA & Day WW. Avanafil for the treatment of erectile dysfunction: a multicenter, randomized, double-blind study in men with diabetes mellitus. Mayo Clinic Proceedings 2012 87 843-852. (doi:10.1016/j. mayocp.2012.06.016)
40. Hatzichristou D, Gambla M, Rubio-Aurioles E, Buvat J, Brock GB, Spera G, Rose L, Lording D & Liang S. Efficacy of tadalafil once daily in men with diabetes mellitus and erectile dysfunction. Diabetic Medicine 2008 25 138-146. (doi:10.1111/j.1464-5491.2007.02338.x)
41. Stirban A, Laude D, Elghozi JL, Sander D, Agelink MW, Hilz MJ & Ziegler D. Acute effects of sildenafil on flow mediated dilatation and cardiovascular autonomic nerve function in type 2 diabetic patients. Diabetes/Metabolism Research and Reviews 2009 25 136-143. (doi:10.1002/dmrr.921)
42. Morano S, Mandosi E, Fallarino M, Gatti A, Tiberti C, Sensi M, Gandini L, Buchetti B, Lenti L, Jannini EA et al. Antioxidant treatment associated with sildenafil reduces monocyte activation and markers of endothelial damage in patients with diabetic erectile dysfunction: a double-blind, placebo-controlled study. European Urology 2007 52 1768-1774. (doi:10.1016/j.eururo.2007.04.042)
43. Lee JW, Park HJ & Park NC. Serum high-sensitivity C-reactive protein levels and response to 5 mg tadalafil once daily in patients with erectile dysfunction and diabetes. Korean Journal of Urology 2013 54 858-864. (doi:10.4111/kju.2013.54.12.858)
44. La Vignera S, Condorelli RA, Vicari E, Lotti F, Favilla V, Morgia G, Maggi M & Calogero AE. Seminal vesicles and diabetic neuropathy: ultrasound evaluation after prolonged treatment with a selective phosphodiesterase-5 inhibitor. Andrology 2013 1 245-250. (doi:10.1111/j.2047-2927.2012.00025.x)
45. Aversa A, Greco E, Bruzziches R, Pili M, Rosano G & Spera G. Relationship between chronic tadalafil administration and improvement of endothelial function in men with erectile dysfunction: a pilot study. International Journal of Impotence Research 2007 19 200-207. (doi:10.1038/sj.ijir.3901513)
46. Rosano GM, Aversa A, Vitale C, Fabbri A, Fini M & Spera G. Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk. European Urology 2005 47 214-220 (discussion 220-222). (doi:10.1016/j.eururo.2004.10.002)
47. Porst H, Brock GB, Kula K, Moncada I, Montorsi F, Basson BR, Kinchen K & Aversa A. Effects of once-daily tadalafil on treatment satisfaction, psychosocial outcomes, spontaneous erections, and measures of endothelial function in men with erectile dysfunction but naive to phosphodiesterase type 5 inhibitors. Journal of Andrology 2012 33 1305-1322. (doi:10.2164/jandrol.111.015289)
48. Palmerini CA, Zucchi A, Fioretti F & Arienti G. Erectile dysfunction and NO: variations of NO penile blood levels before and after sildenafil treatment. International Journal of Impotence Research 2009 21 321-325. (doi:10.1038/ijir.2009.33)
49. Alberti KG & Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabetic Medicine 1998 15 539-553. (doi:10.1002/ (SICI)1096-9136(199807)15:7!539::AID-DIA668O3.0.CO;2-S)
50. Dishy V, Sofowora G, Harris PA, Kandcer M, Zhan F, Wood AJ & Stein CM. The effect of sildenafil on nitric oxide-mediated vasodilation in healthy men. Clinical Pharmacology and Therapeutics 2001 70 270-279. (doi:10.1067/mcp.2001.117995)
51. Katz SD, Balidemaj K, Homma S, Wu H, Wang J & Maybaum S. Acute type 5 phosphodiesterase inhibition with sildenafil enhances flowmediated vasodilation in patients with chronic heart failure. Journal of the American College of Cardiology 2000 36 845-851. (doi:10.1016/ S0735-1097(00)00790-7)
52. Kimura M, Higashi Y, Hara K, Noma K, Sasaki S, Nakagawa K, Goto C, Oshima T, Yoshizumi M & Chayama K. PDE5 inhibitor sildenafil citrate augments endothelium-dependent vasodilation in smokers. Hypertension 2003 41 1106-1110. (doi:10.1161/01.HYP.0000068202.42431.CC)
53. Vlachopoulos C, Tsekoura D, Alexopoulos N, Panagiotakos D, Aznaouridis K & Stefanadis C. Type 5 phosphodiesterase inhibition by sildenafil abrogates acute smoking-induced endothelial dysfunction. American Journal of Hypertension 2004 17 1040-1044. (doi:10.1016/ j.amjhyper.2004.06.027)
54. Giannetta E, Feola T, Gianfrilli D, Pofi R, Dall'Armi V, Badagliacca R, Barbagallo F, Lenzi A & Isidori AM. Is chronic inhibition of phosphodiesterase type 5 cardioprotective and safe? A meta-analysis of randomized controlled trials. BMC Medicine 2014 12 185-203. (doi:10.1186/s12916-014-0185-3)
55. Kaur J. A comprehensive review on metabolic syndrome. Cardiology Research and Practice 2014 2014 943162. (doi:10.1155/2014/943162)
56. Kojima H, Inoue T, Kunimoto H & Nakajima K. IL-6-STAT3 signaling and premature senescence. JAK-STAT 2013 2 e25763. (doi:10.4161/ jkst.25763)
57. Lee IT & Yang CM. Inflammatory signalings involved in airway and pulmonary diseases. Mediators of Inflammation 2013 2013 791231. (doi:10.1155/2013/791231)
58. Badimon L, Romero JC, Cubedo J & Borrell-Pages M. Circulating biomarkers. Thrombosis Research 2012 130 (Suppl 1) S12-S15. (doi:10.1016/j.thromres.2012.08.262)
59. Messner B & Bernhard D. Smoking and cardiovascular disease: mechanisms of endothelial dysfunction and early atherogenesis. Arteriosclerosis, Thrombosis, and Vascular Biology 2014 34 509-515. (doi:10.1161/ATVBAHA.113.300156)
60. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993 362 801-809. (doi:10.1038/362801a0)
61. Solomon H, Man JW & Jackson G. Erectile dysfunction and the cardiovascular patient: endothelial dysfunction is the common denominator. Heart 2003 89 251-253. (doi:10.1136/heart.89.3.251)
62. Thompson IM, Tangen CM, Goodman PJ, Probstfield JL, Moinpour CM & Coltman CA. Erectile dysfunction and subsequent cardiovascular disease. Journal of the AmericanMedical Association 2005 294 2996-3002. (doi:10.1001/jama.294.23.2996)
63. Napoli C & Ignarro LJ. Nitric oxide and pathogenic mechanisms involved in the development of vascular diseases. Archives of Pharmacal Research 2009 32 1103-1108. (doi:10.1007/s12272- 009-1801-1)
64. Schwartz BG, Jackson G, Stecher VJ, Campoli-Richards DM & Kloner RA. Phosphodiesterase type 5 inhibitors improve endothelial function and may benefit cardiovascular conditions. American Journal of Medicine 2013 126 192-199. (doi:10.1016/ j.amjmed.2012.08.015)